NNE1 (also known as NNEI, MN-24 and AM-6527) is an indole-based synthetic cannabinoid, representing a molecular hybrid of APICA and JWH-018 that is an agonist for the cannabinoid receptors, with K<sub>i</sub> values of 60.09 nM at CB<sub>1</sub> and 45.298 nM at CB<sub>2</sub> and EC<sub>50</sub> values of 9.481 nM at CB<sub>1</sub> and 1.008 nM at CB<sub>2</sub>. It was designed by Jos Lange at Abbott in 2010 to serve as an in vivo active pharmacological tool and has a CB<sub>1</sub> receptor pEC<sub>50</sub> of 8.9 with around 80x selectivity over the related CB<sub>2</sub> receptor. It is suspected that metabolic hydrolysis of the amide group of NNE1 may release 1-naphthylamine, a known carcinogen, given the known metabolic liberation (and presence as an impurity) of amantadine in the related compound APINACA, and NNE1 was banned in New Zealand in 2012 as a temporary class drug to stop it being used as an ingredient in then-legal synthetic cannabis products. NNE1 was subsequently found to be responsible for the death of a man in Japan in 2014.
AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects.